特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

慢性腎臓病(CKD):市場分析、疫学、2030年までの市場予測

Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2030

発行 DelveInsight Business Research LLP 商品コード 938680
出版日 ページ情報 英文 215 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
慢性腎臓病(CKD):市場分析、疫学、2030年までの市場予測 Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2030
出版日: 2020年05月01日 ページ情報: 英文 215 Pages
概要

慢性腎疾患(CKD)市場は、主要7ヶ国(米国、ドイツ、フランス、イタリア、スペイン、英国、日本)において予測期間中に5.9%のCAGRで成長する見通しです。

当レポートでは、主要7ヶ国における慢性腎疾患(CKD)市場について調査しており、市場の現状や予測、成長および抑制要因、主要企業の製品や臨床試験・開発情報、国別の市場分析などの情報を提供しています。

目次

第1章 主な洞察

第2章 慢性腎臓病の概要

第3章 慢性腎臓病のSWOT分析

第4章 慢性腎臓病(CKD) 市場概要

  • 2017年の市場シェア分布
  • 2030年の市場シェア分布

第5章 疾患の背景と概要

  • イントロダクション
  • CKDのKDIGO(Kidney Disease: Improving Global Outcomes)分類
  • CKDに関連するリスク要因
  • 兆候と症状
  • 病態生理
  • 合併症
  • 病気の進行
  • 診断、スクリーニングおよび予防

第6章 疫学と患者人口

  • 主な調査結果
  • 主要7ヶ国のCKDの総有病患者数
  • 米国
    • 前提条件・根拠
    • 診断されたCKDの有病例
    • 病期別CKDの有病例
    • 病因別CKDの流行例
    • CKDに関連する併存疾患
    • CKDの透析依存性
  • 欧州5ヶ国
    • 前提条件・根拠
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第7章 治療と管理

  • バイオシミラー
  • CKDの治療ガイドライン
    • KDIGOの診療ガイドライン
    • NICEのガイドライン
  • ケーススタディ
    • CKD患者の転帰の改善
  • CKD患者の見通し

第8章 潜在的なニーズ

第9章 市販製品

  • Epogen (Epoetin alfa):Amgen
    • 製品説明
    • 製品開発活動
    • 安全性と有効性
    • Aranesp (Darbepoetin alfa):Amgen
  • Feraheme:Amag Pharmaceuticals
  • Parsabiv (etelcalcetide): Amgen
  • Sensipar (Cinacalcet): Amgen
  • Auryxia: Keryx Biopharmaceuticals
  • Paricalcitol (Zemplar): AbbVie
  • Velphoro(Sucroferric oxyhydroxide): Vifor Pharma
  • Rayaldee (CTAP101): OPKO IP Holdings II, Inc.|OPKO Health, Inc.
    • 薬品の概要
    • その他の開発活動
    • 臨床開発
    • 臨床試験情報
  • CKD-11101: Chong Kun Dang Pharmaceuticals
    • 臨床試験情報

第10章 新たな治療法

  • Daprodustat:GlaxoSmithKline
  • Vadadustat:Akebia Therapeutics
  • Roxadustat: FibroGen/Astellas Pharma/ AstraZeneca
  • Empagliflozin: Boehringer Ingelheim
  • Veverimer:Tricida
  • Dapagliflozin: AstraZeneca
  • Ziltivekimab: Corvidia Therapeutics
    • Product Description
  • Bardoxolone methyl: Reata Pharmaceuticals.

第11章 CKD:主要7ヶ国の市場分析

  • 主な調査結果
  • 主要7ヶ国のCKDの総市場規模

第12章 市場の展望:主要7ヶ国

第13章 国別市場規模

第14章 米国

第15章 欧州5ヶ国・日本

  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第16章 市場アクセスと償還

第17章 市場の成長要因

第18章 市場の抑制要因

第19章 付録

  • レポート調査手法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Chronic Kidney Disease (CKD) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total Prevalent Patient Population of CKD in 7MM (2017-2030)
  • Table 3: Diagnosed Prevalent Cases of CKD in the United States (2017-2030)
  • Table 4: Prevalent Cases of CKD by stage in the United States (2017-2030)
  • Table 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)
  • Table 6: Comorbidities associated with CKD in the United States (2017-2030)
  • Table 7: Dialysis dependency in the United States (2017-2030)
  • Table 8: Diagnosed Prevalent Cases of CKD in Germany (2017-2030)
  • Table 9: Prevalent Cases of CKD by stage in Germany (2017-2030)
  • Table 10: Prevalent cases of CKD by etiologies in Germany (2017-2030)
  • Table 11: Comorbidities associated with CKD in Germany (2017-2030)
  • Table 12: Dialysis dependency in Germany (2017-2030)
  • Table 13: Diagnosed Prevalent Cases of CKD in France (2017-2030)
  • Table 14: Prevalent Cases of CKD by stage in France (2017-2030)
  • Table 15: Prevalent cases of CKD by etiologies in France (2017-2030)
  • Table 16: Comorbidities associated with CKD in France (2017-2030)
  • Table 17: Dialysis dependency in France (2017-2030)
  • Table 18: Diagnosed Prevalent Cases of CKD in Italy (2017-2030)
  • Table 19: Prevalent Cases of CKD by stage in Italy (2017-2030)
  • Table 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)
  • Table 21: Comorbidities associated with CKD in Italy (2017-2030)
  • Table 22: Dialysis dependency in Italy (2017-2030)
  • Table 23: Diagnosed Prevalent Cases of CKD in Spain (2017-2030)
  • Table 24: Prevalent Cases of CKD by stage in Spain (2017-2030)
  • Table 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)
  • Table 26: Comorbidities associated with CKD in Spain (2017-2030)
  • Table 27: Dialysis dependency in Spain (2017-2030)
  • Table 28: Diagnosed Prevalent Cases of CKD in the United Kingdom (2017-2030)
  • Table 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)
  • Table 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)
  • Table 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)
  • Table 32: Dialysis dependency in the United Kingdom (2017-2030)
  • Table 33: Diagnosed Prevalent Cases of CKD in Japan (2017-2030)
  • Table 34: Prevalent Cases of CKD by stage in Japan (2017-2030)
  • Table 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)
  • Table 36: Comorbidities associated with CKD in Japan (2017-2030)
  • Table 37: Dialysis dependency in Japan (2017-2030)
  • Table 38: Summary of ESAs:
  • Table 39: CTAP101, Clinical Trial Description, 2020
  • Table 40: CKD-1101, Clinical Trial Description, 2020
  • Table 41: Daprodustat, Clinical Trial Description, 2020
  • Table 42: Vadadustat, Clinical Trial Description, 2020
  • Table 43: Roxadustat, Clinical Trial Description, 2020
  • Table 44: Empagliflozin, Clinical Trial Description, 2020
  • Table 45: Veverimer, Clinical Trial Description, 2020
  • Table 46: Dapagliflozin, Clinical Trial Description, 2020
  • Table 47: Ziltivekimab, Clinical Trial Description, 2020
  • Table 48: Bardoxolone methyl, Clinical Trial Description 2020
  • Table 49: 7 Major Market Size of CKD in USD Million (2017-2030)
  • Table 50: The US Market size of CKD in USD Million (2017-2030)
  • Table 51: The US market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 52: The US market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 53: Germany Market size of CKD in USD Million (2017-2030)
  • Table 54: Germany market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 55: Germany market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 56: France Market size of CKD in USD Million (2017-2030)
  • Table 57: France market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 58: France market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 59: Italy Market size of CKD in USD Million (2017-2030)
  • Table 60: Italy market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 61: Italy market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 62: Spain Market size of CKD in USD Million (2017-2030)
  • Table 63: Spain market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 64: Spain market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 65: The CKD Market size of CKD in USD Million (2017-2030)
  • Table 66: The UK market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 67: The UK market size of CKD by Therapies (NDD) in USD Million (2017-2030)
  • Table 68: Japan Market size of CKD in USD Million (2017-2030)
  • Table 69: Japan market size of CKD by Therapies (DD) in USD Million (2017-2030)
  • Table 70: Japan market size of CKD by Therapies (NDD) in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Total Prevalent Patient Population of CKD in 7MM (2017-2030)
  • Figure 3: Diagnosed prevalent cases of CKD in the United States (2017-2030)
  • Figure 4: Prevalent Cases of CKD by stage in the United States (2017-2030)
  • Figure 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)
  • Figure 6: Comorbidities associated with CKD in the United States (2017-2030)
  • Figure 7: Dialysis dependency in the United States (2017-2030)
  • Figure 8: Diagnosed prevalent cases of CKD in Germany (2017-2030)
  • Figure 9: Prevalent Cases of CKD by stage in Germany (2017-2030)
  • Figure 10: Prevalent cases of CKD by etiologies in the Germany (2017-2030)
  • Figure 11: Comorbidities associated with CKD Germany (2017-2030)
  • Figure 12: Dialysis dependency in Germany (2017-2030)
  • Figure 13: Diagnosed prevalent cases of CKD in the France (2017-2030)
  • Figure 14: Prevalent Cases of CKD by stage in France (2017-2030)

Figure15: Prevalent cases of CKD by etiologies in France (2017-2030)

  • Figure 16: Comorbidities associated with CKD in France (2017-2030)
  • Figure 17: Dialysis dependency in France (2017-2030)
  • Figure 18: Diagnosed prevalent cases of CKD in Italy (2017-2030)
  • Figure 19: Prevalent Cases of CKD by stage in Italy (2017-2030)
  • Figure 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)
  • Figure 21: Comorbidities associated with CKD in Italy (2017-2030)
  • Figure 22: Dialysis dependency in Italy (2017-2030)
  • Figure 23: Diagnosed prevalent cases of CKD in Spain (2017-2030)
  • Figure 24: Prevalent Cases of CKD by stage in Spain (2017-2030)
  • Figure 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)
  • Figure 26: Comorbidities associated with CKD in Spain (2017-2030)
  • Figure 27: Dialysis dependency in Spain (2017-2030)
  • Figure 28: Diagnosed prevalent cases of CKD in the United Kingdom (2017-2030)
  • Figure 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)
  • Figure 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)
  • Figure 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)
  • Figure 32: Dialysis dependency in the United Kingdom (2017-2030)
  • Figure 33: Diagnosed prevalent cases of CKD in Japan (2017-2030)
  • Figure 34: Prevalent Cases of CKD by stage in Japan (2017-2030)
  • Figure 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)
  • Figure 36: Comorbidities associated with CKD in Japan (2017-2030)
  • Figure 37: Dialysis dependency in the Japan (2017-2030)
  • Figure 38: Steps in Manufacturing a Biologic Drug
  • Figure 39: Unmet Needs of Chronic Kidney Disease (CKD)
  • Figure 40: 7 Major Market Size of CKD in USD Million (2017-2030)
  • Figure 41: Market Size of CKD in the United States, USD Millions (2017-2030)
  • Figure 42: The U.S. market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 43: The U.S. market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 44: Market Size of CKD in Germany, USD Millions (2017-2030)
  • Figure 45: Germany market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 46: Germany market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 47: Market Size of CKD in France, USD Millions (2017-2030)
  • Figure 48: France market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 49: France market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 50: Market Size of CKD in Italy, USD Millions (2017-2030)
  • Figure 51: Italy market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 52: Italy market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 53: Market Size of CKD in Spain, USD Millions (2017-2030)
  • Figure 54: Spain market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 55: Spain market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 56: Market Size of CKD in the UK, USD Millions (2017-2030)
  • Figure 57: The UK market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 58: The UK market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 59: Market Size of CKD in Japan, USD Millions (2017-2030)
  • Figure 60: Japan market size of CKD by therapies (DD) in USD Million (2017-2030)
  • Figure 61: Japan market size of CKD by therapies (NDD) in USD Million (2017-2030)
  • Figure 62: Key Takeaways for Market Access and Reimbursement of CKD Treatment
  • Figure 63: Market Drivers
  • Figure 64: Market Barriers
目次
Product Code: DIEI0056

DelveInsight's 'Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of CKD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic kidney disease (CKD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic kidney disease (CKD) - Disease Understanding and Treatment Algorithm

Chronic kidney disease (CKD) is a syndrome where there are persistent alterations in kidney structure, function, or both with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, changes in output or quality of urine and growth delay in children, these changes are most often recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. The most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis.

Several aspects need to be considered when managing patients with CKD, including controlling further nephron injury, normalizing single-nephron hyperfiltration, controlling CKD-related complications and preparing the patient for kidney replacement therapy. At the core of these is the principle of 'the earlier, the better', which is the effort to reduce the progression to ESRD and optimize renal outcomes.

Chronic Kidney Disease Diagnosis

The clinical presentation of CKD depends on the underlying disorder and the severity of renal impairment. Patients with early stages of CKD (G1-G2) are usually asymptomatic, but from CKD G3 onwards, patients may experience weakness related to anemia and polyuria. CKD can be detected during a routine periodic health assessment, during the evaluation of individuals at risk of CKD, as a consequence of the incidental finding of abnormal laboratory values in connection with another acute or chronic illness, during an investigation of symptoms and/or signs relating to the kidneys or urinary tract (such as hematuria) or after the discovery of abnormal laboratory values in a population-based screening program.

Chronic Kidney Disease Treatment

It covers the details of conventional and current medical therapies available in the Chronic Kidney Disease market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

The DelveInsight Chronic Kidney Disease market report gives a thorough understanding of CKD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides CKD treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Chronic kidney disease Epidemiology

The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030. According to DelveInsight, the total number of prevalent cases of Chronic kidney disease (CKD) in 7 MM was found to be 122,704,658 in the year 2017.

Chronic kidney disease Drug Chapters

This segment of the Chronic Kidney Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details and the latest news and press releases.

The chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as Erythropoietin stimulating agents (ESA), Angiotensin-converting-enzyme inhibitors and Angiotensin receptor blockers (ACE-I and ARBs), Antidiabetics, Secondary Hyperparathyroidism Treatment (SHPT), and Urate Lowering Therapies.

Chronic kidney disease Marketed Drugs

Aranesp (darbepoetin alfa): Amgen

Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating protein that is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. It is a synthetic form of erythropoietin that stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy and works similar like endogenous erythropoietin

Chronic kidney disease Emerging Drugs

Daprodustat: GlaxoSmithKline

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The product is being developed by GlaxoSmithKline and company has filed the application to the Japan authorities for the treatment of Anemia Associated with Chronic Kidney Disease.

Chronic Kidney Disease Market Outlook

The Chronic kidney disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Chronic kidney disease in 7MM is expected to undergo a major positive shift during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of CKD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. As per DelveInsight's analysis the market size for CKD is expected to increase with a CAGR of 5.9% during the forecast period for 7MM.

Key Findings

This section includes a glimpse of the Chronic Kidney Disease market in 7MM.

The United States Market Outlook

This section provides the total Chronic Kidney Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Chronic Kidney Disease market size and market size by therapies in Germany, France, Italy, Spain and the United Kingdom is provided in this section.

Japan Market Outlook

The total Chronic Kidney Disease market size and market size by therapies in Japan is also mentioned.

Chronic kidney disease Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Kidney Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Kidney Disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Chronic Kidney Disease emerging therapies.

Reimbursement Scenario in Chronic Kidney Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Chronic Kidney Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Kidney Disease market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Chronic Kidney Disease Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Chronic Kidney Disease, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Chronic Kidney Disease epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Kidney Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Kidney Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Kidney Disease market

Report Highlights:

  • In the coming years, Chronic Kidney Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Kidney Disease. Launch of emerging therapies, will significantly impact the Chronic Kidney Disease market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Kidney Disease
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Kidney Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Kidney Disease Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Chronic Kidney Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Kidney Disease Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chronic Kidney Disease total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Kidney Disease Market Size during the forecast period (2017-2030)?
  • At what CAGR, the Chronic Kidney Disease market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Kidney Disease market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Kidney Disease market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Chronic Kidney Disease?
  • What is the historical Chronic Kidney Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Chronic Kidney Disease in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Kidney Disease?
  • Out of all 7MM countries, which country would have the highest Incident population of Chronic Kidney Disease during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Chronic Kidney Disease along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic Kidney Disease (CKD) in USA, Europe and Japan?
  • What are the Chronic Kidney Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy etc.?
  • How many companies are developing therapies for the treatment of Chronic Kidney Disease?
  • How many therapies are developed by each company for the treatment of Chronic Kidney Disease?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Chronic Kidney Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Kidney Disease and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Kidney Disease?
  • What are the global historical and forecasted market of Chronic Kidney Disease?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Kidney Disease market
  • To understand the future market competition in the Chronic Kidney Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Kidney Disease in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Kidney Disease market
  • To understand the future market competition in the Chronic Kidney Disease market

Table of Contents

1. Key Insights

2. Executive Summary of Chronic Kidney Disease

3. SWOT Analysis for Chronic Kidney Disease

4. Chronic Kidney Disease (CKD) Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2017
  • 4.2. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. The KDIGO classification of CKD
  • 5.3. Risk factors associated with CKD
  • 5.4. Signs and symptoms
  • 5.5. Pathophysiology
  • 5.6. Complications
  • 5.7. Disease Progression
  • 5.8. Diagnosis, Screening and Prevention

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)

Country Wise-Epidemiology of CKD

  • 6.3. The United States
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Diagnosed Prevalent cases of CKD
    • 6.3.3. Prevalent cases of CKD by stage
    • 6.3.4. Prevalent cases of CKD by etiologies in the United States
    • 6.3.5. Comorbidities associated with CKD in the United States
    • 6.3.6. Dialysis Dependency in CKD
  • 6.4. EU-5
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Germany
      • 6.4.2.1. Diagnosed Prevalent cases of CKD in Germany
      • 6.4.2.2. Prevalent cases of CKD by stage in Germany
      • 6.4.2.3. Prevalent cases of CKD by etiologies in Germany
      • 6.4.2.4. Comorbidities associated with CKD in Germany
      • 6.4.2.5. Dialysis Dependency in CKD in Germany
    • 6.4.3. France
      • 6.4.3.1. Diagnosed Prevalent cases of CKD in France
      • 6.4.3.2. Prevalent cases of CKD by stage in France
      • 6.4.3.3. Prevalent cases of CKD by etiologies in France
      • 6.4.3.4. Comorbidities associated with CKD in France
      • 6.4.3.5. Dialysis Dependency in CKD in France
    • 6.4.4. Italy
      • 6.4.4.1. Diagnosed Prevalent cases of CKD in Italy
      • 6.4.4.2. Prevalent cases of CKD by stage in Italy
      • 6.4.4.3. Prevalent cases of CKD by etiologies in Italy
      • 6.4.4.4. Comorbidities associated with CKD in Italy
      • 6.4.4.5. Dialysis Dependency in CKD in Italy
    • 6.4.5. Spain
      • 6.4.5.1. Diagnosed Prevalent cases of CKD in Spain
      • 6.4.5.2. Prevalent cases of CKD by stage in Spain
      • 6.4.5.3. Prevalent cases of CKD by etiologies in Spain
      • 6.4.5.4. Comorbidities associated with CKD in Spain
      • 6.4.5.5. Dialysis Dependency in CKD in Spain
    • 6.4.6. The United Kingdom
      • 6.4.6.1. Diagnosed Prevalent cases of CKD in the United Kingdom
      • 6.4.6.2. Prevalent cases of CKD by stage in the United Kingdom
      • 6.4.6.3. Prevalent cases of CKD by etiologies in the United Kingdom
      • 6.4.6.4. Comorbidities associated with CKD in the United Kingdom
      • 6.4.6.5. Dialysis Dependency in CKD in the United Kingdom
    • 6.4.7. Japan
      • 6.4.7.1. Assumption and Rationale
      • 6.4.7.2. Diagnosed Prevalent cases of CKD in Japan
      • 6.4.7.3. Prevalent cases of CKD by stage in Japan
      • 6.4.7.4. Prevalent cases of CKD by etiologies in Japan
      • 6.4.7.5. Comorbidities associated with CKD in Japan
      • 6.4.7.6. Dialysis Dependency in CKD in Japan

7. Treatment and Management

  • 7.1. Biosimilars
  • 7.2. Treatment guidelines for CKD
    • 7.2.1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline
    • 7.2.2. NICE Guidelines
  • 7.3. Case Study
    • 7.3.1. Improving Outcomes for Patients with Chronic Kidney Disease
  • 7.4. Patient Journey for CKD

8. Unmet Needs

9. Marketed Products

  • 9.1. Epogen (Epoetin alfa): Amgen
    • 9.1.1. Product Description
    • 9.1.2. Product Developmental Activity
    • 9.1.3. Safety and Efficacy
    • 9.1.4. Aranesp (Darbepoetin alfa): Amgen
    • 9.1.5. Product Description
    • 9.1.6. Product Developmental Activity
    • 9.1.7. Safety and Efficacy
  • 9.2. Feraheme: Amag Pharmaceuticals
    • 9.2.1. Product Description
    • 9.2.2. Product Developmental Activity
    • 9.2.3. Safety and Efficacy
  • 9.3. Parsabiv (etelcalcetide): Amgen
    • 9.3.1. Product Description
    • 9.3.2. Product Developmental Activity
    • 9.3.3. Safety and Efficacy
  • 9.4. Sensipar (Cinacalcet): Amgen
    • 9.4.1. Product Description
    • 9.4.2. Product Developmental Activity
    • 9.4.3. Safety and Efficacy
  • 9.5. Auryxia: Keryx Biopharmaceuticals
    • 9.5.1. Product Description
    • 9.5.2. Product Developmental Activity
    • 9.5.3. Safety and Efficacy
  • 9.6. Paricalcitol (Zemplar): AbbVie
    • 9.6.1. Product Description
    • 9.6.2. Product Developmental Activity
    • 9.6.3. Safety and Efficacy
  • 9.7. Velphoro(Sucroferric oxyhydroxide): Vifor Pharma
    • 9.7.1. Product Description
    • 9.7.2. Product Developmental Activity
    • 9.7.3. Safety and Efficacy
  • 9.8. Rayaldee (CTAP101): OPKO IP Holdings II, Inc.|OPKO Health, Inc.
    • 9.8.1. Drug Description
    • 9.8.2. Other Developmental Activities
    • 9.8.3. Clinical Development
    • 9.8.4. Clinical Trials Information
    • 9.8.5. Safety and Efficacy
  • 9.9. CKD-11101: Chong Kun Dang Pharmaceuticals
    • 9.9.1. Product Description
    • 9.9.2. Other Developmental Activities
    • 9.9.3. Clinical Development
    • 9.9.4. Clinical trials information
    • 9.9.5. Safety and Efficacy

10. Emerging Therapies

  • 10.1. Daprodustat: GlaxoSmithKline
    • 10.1.1. Drug Description
    • 10.1.2. Other Developmental Activities
    • 10.1.3. Clinical Development
      • 10.1.3.1. Clinical trials information
    • 10.1.4. Safety and Efficacy
  • 10.2. Vadadustat: Akebia Therapeutics
    • 10.2.1. Drug Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
      • 10.2.3.1. Clinical trials information
    • 10.2.4. Safety and Efficacy
  • 10.3. Roxadustat: FibroGen/Astellas Pharma/ AstraZeneca
    • 10.3.1. Drug Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
      • 10.3.3.1. Clinical trials information
    • 10.3.4. Safety and Efficacy
  • 10.4. Empagliflozin: Boehringer Ingelheim
    • 10.4.1. Drug Description
    • 10.4.2. Other Developmental Activities
    • 10.4.3. Clinical Development
      • 10.4.3.1. Clinical trials information
    • 10.4.4. Safety and Efficacy
  • 10.5. Veverimer: Tricida
    • 10.5.1. Drug Description
    • 10.5.2. Other Developmental Activities
    • 10.5.3. Clinical Development
      • 10.5.3.1. Clinical trials information
    • 10.5.4. Safety and Efficacy
  • 10.6. Dapagliflozin: AstraZeneca
    • 10.6.1. Drug Description
    • 10.6.2. Other Developmental Activities
    • 10.6.3. Clinical Development
      • 10.6.3.1. Clinical trials information
    • 10.6.4. Safety and Efficacy
  • 10.7. Ziltivekimab: Corvidia Therapeutics
    • 10.7.1. Product Description
    • 10.7.2. Clinical Development
      • 10.7.2.1. Clinical Trials Information
    • 10.7.3. Safety and Efficacy
  • 10.8. Bardoxolone methyl: Reata Pharmaceuticals.
    • 10.8.1. Drug Description
    • 10.8.2. Other Developmental Activities
    • 10.8.3. Clinical Development
    • 10.8.4. Safety and Efficacy

11. CKD: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Total Market Size of CKD in 7MM

12. Market Outlook: 7 MM

13. Country-wise Market Size

14. United States

  • 14.1. Total Market size of CKD
  • 14.2. CKD Market Size by Therapies (Dialysis Dependent)
  • 14.3. CKD Market Size by Therapies (Non-Dialysis Dependent)

15. EU5 Countries

  • 15.1. Germany
    • 15.1.1. Total Market size of CKD
    • 15.1.2. CKD Market Size by Therapies (DD)
    • 15.1.3. CKD Market Size by Therapies (NDD)
  • 15.2. France
    • 15.2.1. Total Market size of CKD
    • 15.2.2. CKD Market Size by Therapies (DD)
    • 15.2.3. CKD Market Size by Therapies
  • 15.3. Italy
    • 15.3.1. Total Market size of CKD
    • 15.3.2. CKD Market Size by Therapies (DD)
    • 15.3.3. CKD Market Size by Therapies
  • 15.4. Spain
    • 15.4.1. Total Market size of CKD
    • 15.4.2. CKD Market Size by Therapies (DD)
    • 15.4.3. CKD Market Size by Therapies (NDD)
  • 15.5. United Kingdom
    • 15.5.1. Total Market size of CKD
    • 15.5.2. CKD Market Size by Therapies (DD)
    • 15.5.3. CKD Market Size by Therapies (NDD)
  • 15.6. Japan
    • 15.6.1. Total Market size of CKD
    • 15.6.2. CKD Market Size by Therapies (DD)
    • 15.6.3. CKD Market Size by Therapies (NDD)

16. Market Access and Reimbursement

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight